Search Results
36 items found for "mutation"
- Functional Assessment of Cancer-Linked Mutations in Sensitive Regions of Regulators of G Protein Signaling Predicted by Three-Dimensional Missense Tolerance Ratio Analysis
< GPCR News < GPCRs in Oncology and Immunology Functional Assessment of Cancer-Linked Mutations in Sensitive Intolerant and tolerant-control residues that overlap with pathogenic cancer mutations reported in the Identified intolerant residues with reported cancer-linked mutations RGS14-R173C/H and RGS4-K125Q/E126K , including cancer-linked mutations in regulator of G protein signaling (RGS) proteins. We found that 3DMTR more accurately classifies loss-of-function mutations in RGS proteins than other
- Mutation Patterns Predict Drug Sensitivity in Acute Myeloid Leukemia
< GPCR News < GPCRs in Oncology and Immunology Mutation Patterns Predict Drug Sensitivity in Acute Myeloid We also integrated large public datasets to understand the co-occurring mutation patterns and further investigated the mutation profiles in the single cells. to some drug classes, such as MEK inhibitors for RAS-mutated leukemia. It provides a framework for categorizing patients with AML by mutations that enable drug sensitivity
- The Effect of Cancer-Associated Mutations on Ligand Binding and Receptor Function - A Case for the 5-HT2C Receptor
< GPCR News < GPCRs in Oncology and Immunology The Effect of Cancer-Associated Mutations on Ligand Binding In this study, we aimed to investigate the effects of cancer patient-derived 5-HT2C receptor mutations By filtering the sequencing data from the Genomic Data Commons data portal (GDC), we selected 12 mutations These two mutations may disrupt the conserved ionic interaction between E6.30 and R3.50, and thus increase Such mutations may affect serotonin-mediated signaling in tumor cells as well as treatment strategies
- Pan-cancer functional analysis of somatic mutations in G protein-coupled receptors
< GPCR News < GPCRs in Oncology and Immunology Pan-cancer functional analysis of somatic mutations in Here we used a dataset of mutations found in patient samples derived from the Genomic Data Commons and We explored cancer-related mutation patterns in all GPCR classes combined and individually. While the location of the mutations across the protein domains did not differ significantly in the two datasets, a mutation enrichment in cancer patients was observed among class-specific conserved motifs
- Ultrasensitive dose-response for asbestos cancer risk implied by new inflammation-mutation model
Oncology and Immunology Ultrasensitive dose-response for asbestos cancer risk implied by new inflammation-mutation asbestos) fibers in humans and experimental animals are thought to involve modes of action driven by mutations A recent Inflammation Somatic Mutation (ISM) theory of cancer posits instead that tissue-damage-associated promote cancer, but rather is a requisite co-initiator (acting together with as few as two somatic mutations Author Kenneth T Bogen Tags Asbestos , Cytotoxicity , Inflammation , Lung cancer , Mesothelioma , Mutation
- Systems modeling of oncogenic G-protein and GPCR signaling reveals unexpected differences in downstream pathway activation
One promising potential application of such mathematical models is the study of how disease-causing mutations develop a mechanistic mathematical model of a G-protein coupled receptor signaling network that is mutated Modeling the two major, mutually-exclusive, oncogenic mutations (Gαq/11 and CysLT2R) revealed the potential This led us to hypothesize that CYSLTR2 mutations in UM must co-occur with other mutations to activate FAK/YAP/TAZ signaling, and our bioinformatic analysis uncovers a role for co-occurring mutations involving
- Spliceosome mutations are associated with clinical response in a phase 1b/2 study of the PLK1 inhibitor onvansertib in combination with decitabine in relapsed or refractory acute myeloid leukemia
< GPCR News < GPCRs in Oncology and Immunology Spliceosome mutations are associated with clinical response The gene signature was evaluated in independent datasets and used to identify associated mutated genes In the phase 1b/2 trial, patients with SF mutations (SRSF2, SF3B1) had a higher CR/CRi rate (50%) compared to those without SF mutations (9%). a potential therapy in R/R AML patients, particularly those with high OXPHOS gene expression and SF mutations
- Clinical, pathophysiologic, genetic and therapeutic progress in Primary Bilateral Macronodular Adrenal Hyperplasia
nature of PBMAH and familial aggregation, led to the identification of germline heterozygous inactivating mutations the ARMC5 gene, in 20-25% of the apparent sporadic cases and more frequently in familial cases; ARMC5 mutations More recently, combined germline mutations/pathogenic variants and somatic events inactivating the KDM1A
- Proteogenomic landscape and clinical characterization of GH-producing pituitary adenomas/somatotroph pituitary neuroendocrine tumors
Gene ontology analysis was performed for differentially expressed proteins between wild-type and mutant The results suggested that GNAS mutations impact endocrinological features in acromegaly through GPCR These results identified a biological connection between GNAS mutations and the clinical and biochemical
- Dr. GPCR Community Presentation | Adhesion GPCR Workshop 2024 | Dr. GPCR Ecosystem
Zozaya "My doctoral research was focused on investigating the cellular effects of missense lung cancer-mutations
- Distinct Activation Mechanisms of CXCR4 and ACKR3 Revealed by Single-Molecule Analysis of their Conformational Landscapes
CXCR4 only responds to wild-type CXCL12 and is sensitive to mutation of the chemokine. responds to CXCL12, CXCL12 variants, other peptides and proteins, and is relatively insensitive to mutation
- Identification of S1PR4 as an immune modulator for favorable prognosis in HNSCC through machine learning
used with 7 + 3 in adults with newly-diagnosed acute myeloid leukemia (AML), irrespective of the FLT3-mutation 80% and 76%, without differences in MRD- CR rates, OS, or EFS between patients with or without FLT3-mutated
- Ep 86 with Nicole (Nicki) Perry-Hauser
Mutations in aGPCRs have been linked to various neuropsychiatric phenotypes, and my work will provide
- CaaX-motif-adjacent residues influence G protein gamma (Gγ) prenylation under suboptimal conditions
We examined the prenylation of carboxy-terminus (Ct) mutated Gγ in cells exposed to Fluvastatin and prenyl inhibitors and monitored the subcellular localization of fluorescently tagged Gγ subunits and their mutants
- Inhibition of Relaxin Autocrine Signaling Confers Therapeutic Vulnerability in Ovarian Cancer
The adapter protein 3BP2 is mutated in Cherubism.
- Atypical Structure and Function of Typical Chemokine Receptors
This is a rare neurodevelopmental disorder caused by de novo mutations in the GRIN genes that encode
- S1P Signaling Genes as Prominent Drivers of BCR-ABL1-Independent Imatinib Resistance and Six Herbal Compounds as Potential Drugs for Chronic Myeloid Leukemia
Although BCR-ABL1 mutation is a key cause of CML resistance, understanding mechanisms independent of
- Ep 42 with Dr. Randy Hall
Randy’s lab has a special interest in studying disease-associated mutations to human GPCRs that perturb
- Wnt pathway inhibition with the porcupine inhibitor LGK974 decreases trabecular bone but not fibrosis in a murine model with fibrotic bone
dysplasia (FD) of the bone is characterized by fibrotic, expansile bone lesions caused by activating mutations
- Ep 155 with Endocrine Metabolic GPCR Organizers
2012 from the University of Oxford, where her research focused on the cellular mechanisms by which mutations
- Student Flash Presentations | Adhesion GPCR Workshop 2024 | Dr. GPCR Ecosystem
Abstract "Li-Fraumeni syndrome (LFS) is a rare cancer predisposition syndrome caused by a germline mutation Glioblastoma (GBM) is the most prevalent central nervous system tumor in LFS, with TP53 mutations detected that ADGRB3 functions as a tumor suppressor in the brain, and its silencing, in the context of p53 mutation flexibility of GAIN flaps affects aGPCR function under native conditions, we strategically inserted specific mutations
- Ep 146 with Dr Michael Feigin
analysis of cancer drivers by co-developing GECCO, an algorithm for the identification of noncoding mutations He highlighted their interest in non-coding mutations in promoters and the 3'UTR region important for
- Posters | Adhesion GPCR Workshop 2024 | Dr. GPCR Ecosystem
cancers, BAI1-3 expression can be lost through epigenetic silencing, copy number loss or truncating mutations WNT pathway activation in WNT-MB is driven by mutations of the CTNNB1 gene, activating ß-catenin-dependent GAIN-targeted antibodies, and cancer-associated mutations at the GAIN-7TM interface, alter holoreceptor
- Ep 150 with Dr GPCR Team
During that time, I investigated the effect of lung cancer-related mutations in the GAIN domain of the
- Session II | Adhesion GPCR Workshop 2024 | Dr. GPCR Ecosystem
Zozaya "My doctoral research was focused on investigating the cellular effects of missense lung cancer-mutations biochemical and cell-biological approaches using cell-lines overexpressing wild-type and N-glycosylation mutants
- Session V | Adhesion GPCR Workshop 2024 | Dr. GPCR Ecosystem
Mutational experiments on residues of interest showed that restoring the Phe-His interaction in the uncleaving
- Ep 136 with Murat Tunaboylu & Ben Holland
GPCR Podcast << Back to podcast list Murat Tunaboylu & Ben Holland About Murat Tunaboylu "Murat Tunaboylu After switching to biotech, Murat has built cell imaging software and lab robots to accelerate cancer Murat Tunaboylu on the web Antiverse DSV Future of Drug Discovery Podcast Twist Bioscience LinkedIn Twitter
- Intermediate-state-trapped mutants pinpoint G protein-coupled receptor conformational allostery
< GPCR News < GPCRs in Oncology and Immunology Intermediate-state-trapped mutants pinpoint G protein-coupled demonstrate the feasibility of enriching the populations of discrete states via conformation-biased mutants These mutants adopt distinct distributions among five states that lie along the activation pathway of Intermediate-state-trapped mutants will also provide useful information in relation to receptor-G protein